Travis Steed
Stock Analyst at B of A Securities
(2.88)
# 1,727
Out of 4,711 analysts
80
Total ratings
43.75%
Success rate
8.76%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $74.81 | +20.30% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $26.92 | +18.87% | 1 | Nov 5, 2024 | |
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $66.83 | -10.22% | 2 | Jun 25, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $305 → $312 | $227.68 | +37.03% | 6 | May 6, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $29.50 | +52.54% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $1.21 | +147.93% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $364.60 | -13.60% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $266.57 | +10.67% | 3 | Aug 24, 2023 | |
| AXGN Axogen | Reiterates: Overweight | $16 | $15.64 | +2.30% | 5 | Aug 22, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $35.91 | -8.10% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $107.12 | +49.37% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $524.43 | -39.93% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $6.15 | +30.08% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $20.23 | +23.58% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 | $114.23 | +22.56% | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $17.08 | +397.66% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $80.04 | +56.17% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $81.03 | +78.95% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $88.95 | -42.66% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $68.63 | +154.99% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $21.80 | +147.71% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $89.29 | -75.36% | 1 | Jul 17, 2017 |
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $74.81
Upside: +20.30%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $26.92
Upside: +18.87%
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $66.83
Upside: -10.22%
Becton, Dickinson and Company
May 6, 2024
Maintains: Overweight
Price Target: $305 → $312
Current: $227.68
Upside: +37.03%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $29.50
Upside: +52.54%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $1.21
Upside: +147.93%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $364.60
Upside: -13.60%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $266.57
Upside: +10.67%
Axogen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $15.64
Upside: +2.30%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $35.91
Upside: -8.10%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $107.12
Upside: +49.37%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $524.43
Upside: -39.93%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $6.15
Upside: +30.08%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $20.23
Upside: +23.58%
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $114.23
Upside: +22.56%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $17.08
Upside: +397.66%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $80.04
Upside: +56.17%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $81.03
Upside: +78.95%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $88.95
Upside: -42.66%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $68.63
Upside: +154.99%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $21.80
Upside: +147.71%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $89.29
Upside: -75.36%